An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Trial Profile

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 09 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Results assessing the maximum tolerated dose of two administration schedules of E7389 presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2016 According to an Eisai Inc., media release, results from this trial were presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top